Skip to main content
Download PDF

Correlation between perioperative parecoxib use and postoperative acute kidney injury in patients undergoing radical mastectomy: a retrospective cohort analysis

BMC Anesthesiology volume 22, Article number: 155 (2022) Cite this article

Abstract

Background

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed drugs worldwide. However, the effect of NSAIDS on postoperative renal function is still unclear. Few studies have assessed the effects of parecoxib on renal function. Our aim is to investigate a correlation between parecoxib and the presence or absence of AKI postoperatively after a breast cancer surgery operation.

Methods

This was a retrospective cohort study that we performed on our hospitalized database. From January 2012 to August 2021, 3542 female patients undergoing radical mastectomy were enrolled, all data including the patients' information and laboratory results were obtained from electronic medical system. The main outcome was the incidence of AKI postoperatively. AKI was defined in accordance with the KDIGO criteria. Study groups were treated with or without parecoxib. Univariable and multivariable logistic regression analyses were performed.

Results

In our study, about 5.76% experienced AKI. The incidence rate of postoperative AKI (3.49%) within 7 days in the parecoxib group was lower than that in the control group (6.00%, P = 0.05). Compared to the control group, the AKI’s incidence was reduced by 49% (OR = 0.46; 95%CI 0.27–0.97) in parecoxib group in multivariable logistic regression analysis. There was a reduction in the incidence of postoperative AKI in other three subgroups: preoperative eGFR < 90 mL/min·1.73/m2 (OR = 0.52; 95%CI 0.27–0.97), blood loss < 1000 ml (OR = 0.48; 95%CI 0.24–0.96) and non-diabetes (OR = 0.51; 95%CI 0.26–0.98).

Conclusions

Parecoxib was associated with incidence of postoperative acute kidney injury.

Peer Review reports

Background

Acute kidney injury (AKI) is a common postoperative complication among surgical patients [1, 2]. Previous researches suggested that AKI was an independent predictors of increasing length and expenses of hospitalization, and increased mortality in patients with surgery [3, 4]. AKI was a well-recognized complication after cardiac surgery with an incidence of up to 40% [5]. Previous study demonstrated that the postoperative AKI incidence reached to 6.8% in non-cardiac surgery [6]. Besides, among those patients with good physical conditions (low ASA grade) who undergone non-cardiac surgery, the incidence of postoperative AKI could also reach to 6% [7, 8].

There were many risk factors related to in hospital AKI. The most common cause of hospital-acquired AKI is whole-body hypoperfusion, which is also independently associated with perioperative AKI [9]. Up to 60% of cases with sepsis are complicated with AKI, and approximately half of AKI cases are related to sepsis [10]. Besides, AKI was an acute worsening of renal function often associated with the use of contrast agents [11]. Meanwhile, AKI is reported to be a heterogeneous clinical syndrome, with nephrotoxic drugs accounting for 15% of AKI cases [12]. After all, the multifactorial nature of AKI and the numerous nephrotoxic drugs potentially delivered to patients make it very challenging to delineate attributable risk of AKI to specific drugs [13]. However, appropriate drugs that suppress inflammation and oxidative stress might be favorable in treating sepsis-associated AKI [14].

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medicines in the world. Parecoxib was a kind of selective NSAIDs. Tang discovered that the AKI after the non-cardiac surgery was potential associated with parecoxib [15]. Besides, previous studies believed that COX-2 can protect the kidney from ischemia–reperfusion injury in the rats [16]. Therefore, selective COX-2 inhibitors may aggravate renal injury [17]. Above all, the effect of NSAIDS on postoperative renal function is still unclear. The objective of the study was as follows: To evaluate the correlation between postoperative AKI and the parecoxib in the patients undergoing the first surgery for primary breast cancer.

Methods

This was a retrospective cohort study in single hospital between January 1st 2012 and August 31st 2021. The inclusion criteria were as following: (1) patients > 17 years old (2) underwent primary surgical treatment of breast cancer. And the exclusion criteria were as following: (1) surgery duration less than 1 h, (2) preoperative or postoperative creatinine were missing, or (3) preoperative combined chronic kidney disease (CKD), defined as estimate glomerular filtration rate (eGFR) < 60 mL/min/1.73/ m2, ≥ 3 months). Fig. 1 showed the details.

Fig. 1
figure 1

Enrollment of patients undergoing breast cancer surgery

Full size image

Data collection

The following data was collected: (1) demographic information, including age, sex and body mass index(BMI); (2) individual history including preoperative complications and medication history; (3) laboratory data including serum creatinine and eGFR calculated using the CKD Epidemiology Collaboration formula; (4) intraoperative data including emergency, surgical grade, operative time, anesthesia method, ASA grade, amount of fluid infusion and out, intraoperative erythrocyte transfusion volume, amount of blood loss, intraoperative hypotension and vasoactive drugs and (5) postoperative outcomes such as the occurrence of AKI, admission to intensive care unit (ICU) and mortality. The missing values will be imputed by multiple imputation.

Primary outcome and definitions

Study groups were treated with or without parecoxib. Parecoxib group was only administered (40 mg or 80 mg) for one time during the induction period at the discretion of the trained anesthesiology. Whether to use the parecoxib or not was based on the doctor’s preference. Parecoxib doses larger than 80 mg were not included because the routine dose is not more than 80 mg/day based on the drug instructions. Intraoperative hypotension was defined as mean arterial pressure < 65 mmHg for a duration of at least 5 min.

Postoperative AKI was defined by Kidney Disease Improving Global Outcomes classification (KDIGO) without urine output criteria [18]. Increase in serum creatinine by > 1.5-fold from preoperative baseline within 7 days or increase in serum creatinine ≥ 0.3 mg dL−1 within 48 h. The major outcome event was whether the postoperative AKI occurs or not.

Statistical analysis

Sample size was determined setting alpha = 0.05 and power = 0.80. Based on an estimated AKI incidence of 6.3% in control group and 3.6% in parecoxib group, we would need to include approximately 2004 patients. Empowerstats (http://www.empowerstats.com), R statistical software package and SAS statistical software were used for data analysis. Continuous variables are expressed by mean (SD), and classification variables were expressed in frequency and percentage and were analyzed using the Chi-squared test or Fisher exact test. Continuous variables between subgroups were compared by using Kruskal–Wallis test. Logistic stepwise regression was used in multivariate analysis. Bilateral test was used in all statistical analysis. The results of categorical variables were expressed expressed as OR or ‘beta’ and 95% CI; significance was accepted at a P value of less than 0.05.

Results

Parecoxib

Overall, the parecoxib was used by 9.71% (344/3542) of the patients before the end of the surgery. The percentage of AKI in the parecoxib group (12/344, 3.49%) was lower than that control group (192/3198, 6.00%). No statistical differences between the two groups with respect to age, eGFR, alcoholism, anemia, diabetes mellitus, preoperative ACEI, ARB, diuretics, ASA grade, intraoperative erythrocyte transfusion, and intraoperative hypotension were observed (Tables 1 and 2).

Table 1 Baseline demographic data of study population group by parecoxib
Full size table
Table 2 Incident of postoperative AKI in different dose paracoxib
Full size table

Acute kidney injury

In total, 3542 patients were included in this study. AKI incidence was 5.76% (204/3542), with 3.92% (8/204) admission into ICU and mortality rate of 1.96% (4/204). No significant differences in age, BMI, alcohol consumption, the use of ACEI, ARB, intraoperative hemorrhage and admission into ICU were observed between groups. Baseline demographics between groups are shown in Table 3.

Table 3 Baseline demographic data of study population group by AKI
Full size table

Univariable analysis

Univariable analysis was shown in the Fig. 2. By the univariable analysis, the use of parecoxib (OR 0.49; 95% CI 0.27–0.88, P = 0.017), anemia (OR 1.65; 95%CI 1.20–2.26, P = 0.002), hypertension(OR 1.78; 95% CI 1.32–2.42, P < 0.001), diabetes (OR 1.74; 95% CI 1.03–2.92, P = 0.038), the use of CCB ( OR 1.55; 95% CI 1.07–2.25, P = 0.020), diuretics (OR 3.03; 95% CI 1.26–7.33, P = 0.013), eGFR (OR 0.97; 95% CI 0.96 to 0.97, P < 0.001), ASA grade III–V ( OR 1.78; 95% CI 1.30–2.43, P < 0.001), intraoperative erythrocyte transfusion 100-600 ml (OR 1.66; 95% CI 1.11–2.50, P = 0.014), intraoperative erythrocyte transfusion > 1000 ml (OR 2.00; 95% CI 1.25–3.21, P = 0.004), intraoperative hemorrhage between 100-600 ml (OR 1.70; 95% CI 1.02–2.83, P = 0.043) and in fluid amount (OR 1.00; 95% CI 1.00–1.00, P < 0.001) were associated with the postoperative AKI independently. Age, BMI, alcohol consumption, the use of ACEI, ARBs, and operative duration were not correlated with AKI.

Fig. 2
figure 2

Univariable analysis of AKI

Full size image

Multivariable regression analysis

Table 4 showed the results of Multivariable regression analysis. Parecoxib was independently associated with postoperative AKI. Besides, parecoxib might have moderate protective effects on postoperative renal function in the subgroups of eGFR < 90, blood loss < 1000 ml, and non-diabetes groups. For all the three subgroups, the administration of parecoxib leaded to a decreasingly incidence of postoperative AKI.

Table 4 Multivariable regression analysis of postoperative AKI associated with parecoxib
Full size table

Discussion

There are so many factors related to the post-operative AKI (Fig. 2). ASA grade were related to the post-operative AKI which was similar to the previous researches [7]. The Fig. 1 suggested that intraoperative hypotension (MAP < 60 mmHg) was a risk factor to AKI, too [19]. Besides, according to the previous studies [20, 21], preoperative eGFR was one of the most important factors to AKI. The analysis suggested that preoperative eGFR was an independent risk factor in our study.

Over the past years, many researches about the NSAIDs and renal function have been reported. A previous meta-analysis suggested that the AKI was associated to NSAIDs exposure, especially in the elderly patients [22]. And another meta-analysis demonstrated selective COX-2 inhibitors was related with the increasing risk of AKI [23]. However, a study revealed that there were no statistical differences in kidney function between the groups with and without NSAIDs among elderly patients [24]. Even more, a prospective and multicenter study by STARSurg showed that NSAIDs in the postoperative was safer for the patients undergoing gastrointestinal surgery. And the low dose of flurbiprofen axetil (50-100 mg) decrease the rate of AKI after non-cardiac surgery [25, 26].

In our study, 5.76% patients experienced postoperative AKI after breast cancer surgery which was in the scope mentioned in previous studies (1.0–31.0%) [27,28,29]. The incidence of AKI in cancer patients was high, which was closely related to their cachexia or renal injury drugs [30]. And another study showed that non-selective NSAIDs (acetaminophen) was not related to the AKI among the patients undergoing surgery for renal carcinoma [31]. However, administration of parecoxib nearly reached statistical significance in our study (Table 2). One possible explanation might be that breast tumor growth have elevated the level of inflammation [32] and reduced the potential renoprotetive effect of parecoxib. Furthermore, parecoxib showed its potential renoprotective effect in the multivariable analysis (OR = 0.46, 95%CI = 0.24–0.86) in Table 4. Furthermore, the results revealed that parecoxib may still has a stable effect on the partial patients receiving breast cancer surgery as following: eGFR < 90 mL/min·1.73/m2, blood loss < 1000 ml and non-diabetes, which represented preoperative glomerular perfusion and filtration disorder, relatively good cardiovascular status and perfusion. Overall, parecoxib (40 or 80 mg) has a potential protective effect on postoperative AKI.

The mechanism by which parecoxib protects the patient against postoperative AKI is not clear. But it maybe correlated with decreasing the postoperative kidney inflammatory reaction [33]. High-dose flurbiprofen axetil may destroy the inflammatory balance in the tubules [25]. Besides the clinical studies above, an animal experiment by Takaku indicated that a single dose of parecoxib could reduce the inflammation and tubular renal injury in the rats model of ischemic tubular necrotizing nephritis caused by acute hemorrhagic shock [34].

A limitation of the present study was its retrospective nature, and further research involving multi-center, prospective studies is required. And, we only chose the patients above 18 years who received the first breast cancer surgery, and the scope of application of the conclusion was relatively narrow.

Conclusions

Parecoxib (40 or 80 mg) may correlate with relatively low risk of postoperative AKI, in adult patients undergoing breast cancer surgery. Further prospective, multiple centers research are needed to confirm the protective effects on postoperative AKI.

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

References

  1. Kim BR, Yoon S, Song GY, Lee S, Bahk JH, Nam K. The impact of total intravenous anesthesia versus inhalation anesthesia on acute kidney injury after major abdominal surgery: a propensity score analysis. J Anesth. 2021;35(1):112–21.

    Article  Google Scholar 

  2. Silverton NA, Hall IE, Melendez NP, Harris B, Harley JS, Parry SR, et al. Intraoperative urinary biomarkers and acute kidney injury after cardiac surgery. J Cardiothorac Vasc Anesth. 2021;35(6):1691–700.

    Article  CAS  Google Scholar 

  3. Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL, Liu KD. Ongoing clinical trials in AKI. Clin J Am Soc Nephrol. 2012;7(5):861–73.

    Article  Google Scholar 

  4. Tang Y, Li H, Guo Z. Prediction of ICU admission after orthopedic surgery in elderly patients. Pak J Med Sci. 2021;37(4):1179–84.

    Article  Google Scholar 

  5. Mossanen JC, Pracht J, Jansen TU, Buendgens L, Stoppe C, Goetzenich A, Struck J, Autschbach R, Marx G, Tacke F. Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery. Int J Mol Sci. 2017;18(8):1662.

    Article  Google Scholar 

  6. O’Connor ME, Hewson RW, Kirwan CJ, Ackland GL, Pearse RM, Prowle JR. Acute kidney injury and mortality 1 year after major non-cardiac surgery. Br J Surg. 2017;104(7):868–76.

    Article  CAS  Google Scholar 

  7. Iyigun M, Aykut G, Tosun M, Kilercik M, Aksu U, Güler T, Toraman F. Perioperative risk factors of acute kidney injury after non-cardiac surgery: a multicenter, prospective, observational study in patients with low grade American Society of Anesthesiologists physical status. Am J Surg. 2019;218(3):457–61.

    Article  Google Scholar 

  8. Doleman B, Blackwell J, Karangizi A, Butt W, Bhalla A, Lund JN, Williams JP. Anaesthetists stress is induced by patient ASA grade and may impair non-technical skills during intubation. Acta Anaesthesiol Scand. 2016;60(7):910–6.

    Article  CAS  Google Scholar 

  9. Ikeda M, Swide T, Vayl A, Lahm T, Anderson S, Hutchens MP. Estrogen administered after cardiac arrest and cardiopulmonary resuscitation ameliorates acute kidney injury in a sex- and age-specific manner. Crit Care. 2015;19:332.

    Article  Google Scholar 

  10. Li Y, Zhai P, Zheng Y, Zhang J, Kellum JA, Peng Z. Csf2 Attenuated sepsis-induced acute kidney injury by promoting alternative macrophage transition. Front Immunol. 2020;11:1415.

    Article  CAS  Google Scholar 

  11. Yoo J, Hong JH, Lee SJ, Kim YW, Hong JM, Kim CH, Choi JW, Kang DH, Kim YS, Hwang YH, et al. Acute kidney injury after endovascular treatment in patients with acute ischemic stroke. J Clin Med. 2020;9(5):1471.

    Article  Google Scholar 

  12. Wei XM, Jiang S, Li SS, Sun YS, Wang SH, Liu WC, Wang Z, Wang YP, Zhang R, Li W. Endoplasmic reticulum stress-activated PERK-eIF2alpha-ATF4 signaling pathway is involved in the ameliorative effects of ginseng polysaccharides against cisplatin-induced nephrotoxicity in mice. ACS Omega. 2021;6(13):8958–66.

    Article  CAS  Google Scholar 

  13. Ehrmann S, Helms J, Joret A, Martin-Lefevre L, Quenot JP, Herbrecht JE, Benzekri-Lefevre D, Robert R, Desachy A, Bellec F, et al. Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury. Ann Intensive Care. 2019;9(1):106.

    Article  Google Scholar 

  14. Islam MS, Miao L, Yu H, Han Z, Sun H. Ethanol extract of illicium henryi attenuates LPS-induced acute kidney injury in mice via regulating inflammation and oxidative stress. Nutrients. 2019;11(6):1412.

    Article  CAS  Google Scholar 

  15. Tang YZ, Zeng P, Liao Y, Qin Z, Zhang H, Li B, Ouyang W, Li D. Correlation between perioperative parecoxib use and postoperative acute kidney injury in patients undergoing non-cardiac surgery: a retrospective cohort analysis. BMJ Open. 2021;11(8):e047840.

    Article  Google Scholar 

  16. Calistro Neto JP, Torres RdC, Gonçalves GM, Silva LMd, Domingues MAC, Módolo NSP, Barros GAMd. Parecoxib reduces renal injury in an ischemia/reperfusion model in rats. Acta Cir Bras. 2015;30(4):270–6.

    Article  Google Scholar 

  17. Patel NSA, Cuzzocrea S, Collino M, Chaterjee PK, Mazzon E, Britti D, Yaqoob MM, Thiemermann C. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 2007;562(1–2):148–54.

    Article  CAS  Google Scholar 

  18. Foti KE, Wang D, Chang AR, Selvin E, Sarnak MJ, Chang TI, Muntner P, Coresh J. Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States. Kidney Int. 2021;99(3):686–95.

    Article  CAS  Google Scholar 

  19. Gregory A, Stapelfeldt WH, Khanna AK, Smischney NJ, Boero IJ, Chen Q, Stevens M, Shaw AD: Intraoperative Hypotension Is Associated With Adverse Clinical Outcomes After Noncardiac Surgery. Anesth Analg 2020. Online ahead.

  20. Sawhney S, Mitchell M, Marks A, Fluck N, Black C. Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review. BMJ Open. 2015;5(1):e006497.

    Article  Google Scholar 

  21. Toda Y, Sugimoto K. AKI after pediatric cardiac surgery for congenital heart diseases-recent developments in diagnostic criteria and early diagnosis by biomarkers. J Intensive Care. 2017;5:49.

    Article  Google Scholar 

  22. Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256.

    Article  Google Scholar 

  23. Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(4):285–91.

    Article  CAS  Google Scholar 

  24. Amatruda JG, Katz R, Peralta CA, Estrella MM, Sarathy H, Fried LF, Newman AB, Parikh CR, Ix JH, Sarnak MJ, et al. Association of non-steroidal anti-inflammatory drugs with kidney health in ambulatory older adults. J Am Geriatr Soc. 2021;69(3):726–34.

    Article  Google Scholar 

  25. Wang D, Xie W, Li B, Zhao Y, Liu X, Zhang Y, et al. Perioperative use of flurbiprofen axetil on renal function after transurethral prostatectomy: a prospective randomized controlled study. J Nanomater. 2021;2021(1):1–7.

    Google Scholar 

  26. Wang D, Yang SK, Zhao MX, Tang YZ, Ou-Yang W, Zhang H, Liao Q. Low dose of flurbiprofen axetil decrease the rate of acute kidney injury after operation: a retrospective clinical data analysis of 9915 cases. BMC Nephrol. 2020;21(1):52.

    Article  CAS  Google Scholar 

  27. Kim M, Brady JE, Li G. Variations in the risk of acute kidney injury across intraabdominal surgery procedures. Anesth Analg. 2014;119(5):1121–32.

    Article  Google Scholar 

  28. Biteker M, Dayan A, Tekkeşin Aİ, Can MM, Taycı İ, İlhan E, Şahin G. Incidence, risk factors, and outcomes of perioperative acute kidney injury in noncardiac and nonvascular surgery. Am J Surg. 2014;207(1):53–9.

    Article  Google Scholar 

  29. Vaara ST, Bellomo R. Postoperative renal dysfunction after noncardiac surgery. Curr Opin Crit Care. 2017;23(5):440–6.

    Article  Google Scholar 

  30. Lupuşoru M, Lupuşoru G, Ailincăi I, Frățilă G, Andronesi A, Micu E, Banu M, Costea R, Ismail G. Renal replacement therapy in cancer patients with acute kidney injury (Review). Exp Ther Med. 2021;22(2):864.

    Article  Google Scholar 

  31. Varela-Santoyo E, Escamilla-López MI, Izquierdo-Tolosa CD, Arroyave-Ramírez AM, Buerba-Vieregge HH, Dorantes-Heredia R, Motola-Kuba D, Ruiz-Morales JM. Impact of the type of analgesic therapy on postsurgical complications of patients with kidney cancer undergoing nephrectomy. Oncology. 2020;98(2):117–22.

    Article  CAS  Google Scholar 

  32. Javaid N, Choi S. Toll-like receptors from the perspective of cancer treatment. Cancers (Basel). 2020;12(2):297.

    Article  Google Scholar 

  33. Sato Y, Yanagita M. Immune cells and inflammation in AKI to CKD progression. Am J Physiol Renal Physiol. 2018;315(6):F1501–12.

    Article  CAS  Google Scholar 

  34. Takaku M, da Silva AC, Iritsu NI, Vianna PTG, Castiglia YMM. Effects of a single dose of parecoxib on inflammatory response and ischemic tubular injury caused by hemorrhagic shock in rats. Pain Res Treat. 2018;2018:8375746.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by grant from Wujieping Medical Foundation (320.6750.2020-08-25)

Funding

This work was supported by grant from Wujieping Medical Foundation (320.6750.2020–08-25).

Author information

Authors and Affiliations

  1. The Department of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China

    Nan Xu & Sihua Qi

  2. The Department of Anesthesiology, The Third Xiangya Hospital of Central South University, 138 Tongzipo Road, Yuelv District, Changsha, Hunan, China

    Ke Pang

  3. The Department of Pain, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China

    Hongmei Wang

Authors
  1. Nan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ke Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sihua Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hongmei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NX reviewed and analyzed the data and wrote the manuscript. SHQ guided the research and revised the manuscript. NX contributed to the conception and design of the study. MHW aided the research, KP conceived and designed the study, and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Sihua Qi or Hongmei Wang.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the IRB of The fourth Affiliated Hospital of Harbin Medical University (2021-SCILLSC-12). Because of retrospective study, informed consent was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, N., Pang, K., Qi, S. et al. Correlation between perioperative parecoxib use and postoperative acute kidney injury in patients undergoing radical mastectomy: a retrospective cohort analysis. BMC Anesthesiol 22, 155 (2022). https://doi.org/10.1186/s12871-022-01688-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12871-022-01688-4

Keywords

BMC Anesthesiology

ISSN: 1471-2253

Contact us